Strs Ohio raised its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 218.7% during the second quarter, Holdings Channel reports. The firm owned 52,900 shares of the biotechnology company’s stock after buying an additional 36,300 shares during the period. Strs Ohio’s holdings in Momenta Pharmaceuticals were worth $894,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of MNTA. BlackRock Inc. raised its position in Momenta Pharmaceuticals by 64,825.8% in the first quarter. BlackRock Inc. now owns 8,774,070 shares of the biotechnology company’s stock valued at $117,134,000 after buying an additional 8,760,556 shares during the period. State Street Corp raised its position in Momenta Pharmaceuticals by 30.8% in the first quarter. State Street Corp now owns 2,455,449 shares of the biotechnology company’s stock valued at $32,776,000 after buying an additional 577,504 shares during the period. Acadian Asset Management LLC raised its position in Momenta Pharmaceuticals by 322.9% in the second quarter. Acadian Asset Management LLC now owns 696,138 shares of the biotechnology company’s stock valued at $11,762,000 after buying an additional 531,525 shares during the period. Foresite Capital Management III LLC acquired a new position in Momenta Pharmaceuticals during the first quarter valued at $5,749,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new position in Momenta Pharmaceuticals during the first quarter valued at $5,607,000. 87.15% of the stock is owned by hedge funds and other institutional investors.
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) opened at 15.45 on Friday. The company has a 50-day moving average price of $16.58 and a 200-day moving average price of $15.72. Momenta Pharmaceuticals, Inc. has a 12 month low of $10.66 and a 12 month high of $19.90. The company’s market capitalization is $1.14 billion.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business had revenue of $23.57 million during the quarter, compared to the consensus estimate of $24.64 million. During the same quarter last year, the firm earned ($0.31) earnings per share. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. On average, equities analysts anticipate that Momenta Pharmaceuticals, Inc. will post ($1.16) EPS for the current year.
WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Shares Bought by Strs Ohio” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/18/momenta-pharmaceuticals-inc-mnta-shares-bought-by-strs-ohio.html.
A number of analysts recently commented on MNTA shares. Barclays PLC lowered Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $20.00 to $17.00 in a research report on Monday, May 22nd. Cowen and Company reaffirmed a “hold” rating and issued a $15.00 target price on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Maxim Group set a $6.00 target price on Momenta Pharmaceuticals and gave the company a “sell” rating in a research report on Wednesday, May 3rd. Zacks Investment Research lowered Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Finally, BidaskClub raised Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $16.63.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 16,953 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $16.94, for a total transaction of $287,183.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 18,749 shares of company stock valued at $315,531 in the last ninety days. Insiders own 4.40% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
What are top analysts saying about Momenta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Momenta Pharmaceuticals Inc. and related companies.